Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

被引：0
|
作者：
Adams, Richard A.
Fisher, David
Farragher, Susan
Scott, Alastair
Smith, Christopher G.
James, Michelle D.
Cheadle, Jeremy
Nichols, Laura L.
Meade, Angela M.
Kaplan, Richard S.
Wilson, Richard H.
Wasan, Harpreet S.
Maughan, Tim
机构：
[1] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales
[2] MRC, Clin Trials Unit, London, England
[3] ALMAC Diagnost, Craigavon, North Ireland
[4] Cardiff Univ, Cardiff CF10 3AX, S Glam, Wales
[5] Queens Univ Belfast, Belfast, Antrim, North Ireland
[6] Imperial Coll Healthcare Trust, Hammersmith Hosp, London, England
[7] Univ Oxford, Gray Inst Radiat Oncol & Biol, Oxford, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3516
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC)
    Adams, Richard A.
    Fisher, David
    Farragher, Susan
    Jasani, Bharat
    Smith, Christopher G.
    James, Michelle D.
    Cheadle, Jeremy
    Nichols, Laura L.
    Meade, Angela M.
    Kaplan, Richard S.
    Wilson, Richard H.
    Wasan, Harpreet
    Maughan, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [2] Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC)
    Seligmann, J.
    Richman, S.
    Elliott, F.
    Jacobs, B.
    Hemmings, G.
    Barrett, J.
    Tejpar, S.
    Quirke, P.
    Seymour, M.
    VIRCHOWS ARCHIV, 2014, 465 : S1 - S1
  • [3] Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC).
    Seligmann, Jenny F.
    Elliott, Faye
    Richman, Susan
    Jacobs, Bart
    Hemmings, Gemma
    Barrett, Jenny
    Tejpar, Sabine
    Quirke, Philip
    Seymour, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutationson outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
    Stahler, Arndt
    Heinemann, Volker
    Giessen, Clemens Albrecht
    Crispin, Alexander
    Schalhorn, Alexander
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Stauch, Martina
    Qietzsch, Detief
    Neumann, Jens
    Kirchner, Thomas
    Jung, Andreas
    Modest, Dominik Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Influence of mRNA expression of Epiregulin (EREG) and of Amphiregulin (AREG) and RAS mutations on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
    Stahler, A.
    Heinemann, V
    Giessen, C.
    Crispin, A.
    Schalhorn, A.
    Stintzing, S.
    von Weikersthal, Fischer L.
    Vehling-Kaiser, U.
    Stauch, M.
    Quietzsch, D.
    Neumann, J.
    Kirchner, T.
    Jung, A.
    Modest, D. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 81 - 81
  • [6] Concurrent irinotecan, oxaliplatin and uft/lv triple therapy as first-line treatment for advanced colorectal cancer (ACRC)
    Sheikh, H. Y.
    Valle, J. W.
    Palmer, K.
    Sjursen, A.
    Wilson, G.
    Swindel, R.
    Saunders, M. P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 190
  • [7] Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
    Martinez-Balibrea, E.
    Abad, A.
    Aranda, E.
    Sastre, J.
    Manzano, J. L.
    Aparicio, J.
    Garca, T.
    Maestu, I.
    Martinez-Cardus, A.
    Gines, A.
    Guino, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf D.
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
    Aballea, S.
    Najib, M.
    Cure, S.
    O'Neil, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 66
12345